17/03/2016 – Gecko Biomedical has raised €22.5 million ($25.5 million) to get it through the clinic and gain regulatory approval for its biopolymer platform in several indications for tissue reconstruction.

It’s aiming for a first approval within a year–with the first focus on its cardiovascular reconstruction candidate, dubbed GB-02. The goal is to create an entire product portfolio based on its novel polymer that enables guided tissue repair and localized drug delivery…

(visit FierceMedicalDevices)